⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

December 1, 1988European Journal of Clinical Investigation

Prostaglandin E1 and arterial occlusive disease: pharmacological considerations

View Full Paper

Ask AI

Bookmark

Share

Authors

TSTh. SimmetHelmholtz-Institute Ulm BPBernhard A. PeskarCross-Cutting Cardiology

Discussion

Loading...

Member takes

Implication

PGE1 pharmacology in arterial occlusive disease may inform therapy; leaves open clinical efficacy pending controlled trials.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Simmet et al. (1988) studied this question.

synapsesocial.com/papers/6a90824cfdaee66aea8411d8 https://doi.org/10.1111/j.1365-2362.1988.tb01266.x

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1Haemodynamic effects of intra-arterial and intravenous administration of prostaglandin E1 in patients with peripheral arterial disease1986 · 19 citations
2Prostaglandins1975 · 529 citations
3Identification of 13,14‐dihydro‐15‐oxo‐prostaglandin F2α in the circulation during infusions of bradykinin and prostaglandin E2 in man1987 · 10 citations
4Relative activity of prostaglandins E1, A1, E2 and A2 on lipolysis, platelet aggregation, smooth muscle and the cardiovascular system1969 · 66 citations